Assembly Biosciences, Inc. (ASMB)
NASDAQ: ASMB · Real-Time Price · USD
28.41
-2.38 (-7.73%)
At close: Oct 21, 2025, 4:00 PM EDT
28.50
+0.09 (0.32%)
After-hours: Oct 21, 2025, 4:35 PM EDT
Assembly Biosciences Employees
Assembly Biosciences had 73 employees as of December 31, 2024. The number of employees increased by 8 or 12.31% compared to the previous year.
Employees
73
Change (1Y)
8
Growth (1Y)
12.31%
Revenue / Employee
$455,438
Profits / Employee
-$533,753
Market Cap
442.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 73 | 8 | 12.31% |
| Dec 31, 2023 | 65 | -3 | -4.41% |
| Dec 31, 2022 | 68 | -34 | -33.33% |
| Dec 31, 2021 | 102 | -37 | -26.62% |
| Dec 31, 2020 | 139 | 24 | 20.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ASMB News
- 7 days ago - Assembly Biosciences Announces Upcoming Investor Conference Participation - GlobeNewsWire
- 11 days ago - Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe - GlobeNewsWire
- 22 days ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 2 months ago - Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts - Seeking Alpha
- 2 months ago - Assembly Biosciences Announces Pricing of $175 Million in Equity Financings - GlobeNewsWire
- 2 months ago - Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes - GlobeNewsWire
- 2 months ago - Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates - GlobeNewsWire
- 2 months ago - Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus - GlobeNewsWire